Treatment after resistance to cemiplimab

Cemiplimab is an immunotherapy drug used to boost the immune system's attack on certain types of cancer. However, like other drugs, some patients may develop resistance after receiving cimepilimab, meaning that the drug is no longer effective. In this case, here are some treatments to consider:

1.Switching treatment regimens: If a patient develops resistance, doctors may recommend switching to a different treatment regimen, perhaps other immunotherapy drugs or targeted drugs, which may respond better to new anti-cancer strategies. The choice of new treatments needs to be determined based on the patient's specific circumstances and disease type.

2.Combination therapy: Sometimes, combining different types of drugs can improve the effectiveness of treatment. After resistance develops, doctors may consider combining cimepilimab with other anticancer drugs to enhance the effectiveness of treatment. This combination treatment strategy may help overcome drug resistance.

3.Clinical Trials: Patients can participate in ongoing clinical trials to explore new treatment options. Clinical trials often involve drugs or new treatment strategies that are not yet approved, and they may offer new hope for drug-resistant patients.

4.Personalized treatment: Personalized treatment is a treatment plan based on the patient's specific genotype and disease characteristics. Through molecular diagnosis and genetic sequencing, doctors can develop personalized treatment plans for patients to increase the success rate of treatment.

5.Supportive therapy: Although cancer cannot be cured directly, supportive therapy can help patients cope with the symptoms and discomfort of the disease and improve their quality of life. This includes analgesics, anti-nausea medications, psychological support and nutritional management, among others.

Cimeplimab is not currently available in China, so patients cannot purchase it domestically and need to purchase cimeplimab through overseas channels. There are only cimepri monoclonal original drugs abroad, mainly European and American versions. The European version is about 40,000, and the American version is about 100,000. Both are original drugs, and their drug ingredients and efficacy are the same.